Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | CMGC family protein kinase | 0.0055 | 0 | 0.5 |
Brugia malayi | hypothetical protein | 0.0072 | 0.4539 | 0.4539 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.0055 | 0 | 0.5 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.0055 | 0 | 0.5 |
Giardia lamblia | Kinase, CMGC MAPK | 0.0055 | 0 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0055 | 0 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.0055 | 0 | 0.5 |
Echinococcus multilocularis | jun protein | 0.0091 | 1 | 1 |
Onchocerca volvulus | 0.0072 | 0.4539 | 0.5 | |
Echinococcus granulosus | jun protein | 0.0091 | 1 | 1 |
Schistosoma mansoni | jun-related protein | 0.0074 | 0.5236 | 1 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.0055 | 0 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | 0.0091 | 1 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | 0.0091 | 1 | 1 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.0055 | 0 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0055 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0089 | 0.9303 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0055 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0074 | 0.5236 | 1 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.0055 | 0 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0055 | 0 | 0.5 |
Trypanosoma brucei | protein kinase, putative | 0.0055 | 0 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0055 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 5 uM | In vitro concentration which inhibits cloning efficiency of B16 melanoma cells by 50% on a 2-h exposure was determined. | ChEMBL. | 2329559 |
ILS (binding) | = 0 % | In vitro maximum increase in lifespan produced in mice bearing ip B16 melanoma implanted tumor | ChEMBL. | 2329559 |
ILS (functional) | = 46 % | In vitro maximum increase in lifespan produced in mice bearing M5076 reticulum cell sarcoma implanted tumor | ChEMBL. | 2329559 |
ILS (functional) | = 54 % | In vitro maximum increase in lifespan produced in mice bearing ip P388 leukemia | ChEMBL. | 2329559 |
MTD (functional) | = 2 uM day-1 kg-1 | In vitro maximally tolerated dose for B6D2F mice on an every day ip for 10 days regimen. | ChEMBL. | 2329559 |
MTD (functional) | = 4 uM day-1 kg-1 | In vitro maximally tolerated dose for B6D2F1 mice on an ip P388 leukemia every day for 5 days regimen | ChEMBL. | 2329559 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.